



Neuren extends Share Purchase Plan (SPP)

Wednesday, 27 August 2008: Neuren Pharmaceuticals Limited (ASX: NEU) announces that it has extended the Share Purchase Plan closing date to Tuesday 9 September 2008 to give participating shareholders further time to consider the offer.

Neuren announced on 6 August 2008 its intention to make the SPP offer, underwritten up to A\$2.05 million. The updated timetable for the SPP is set out below:

Event	New Date
The SPP Offer closes (Closing Date)	9 September 2008
Proposed share allotment	18 September 2008
Proposed ASX quotation date	19 September 2008

Other details of the SPP are contained in the SPP Offer Document to shareholders. The SPP Offer Document contains specific information about the SPP and the Terms and Conditions upon which the Company makes the offer to shareholders. Shareholders are strongly encouraged to read the SPP Offer Document carefully and seek further assistance where necessary.

About Neuren

Neuren Pharmaceuticals is a biopharmaceutical company developing novel therapeutics in the fields of brain injury, neurological diseases and conditions, and metabolic disorders including cancer. The Neuren portfolio comprises eight product families targeting markets with large unmet needs and limited competition. Neuren has three clinical-stage molecules — Glypromate[®], Motiva[™] and NNZ-2566—focused on a range of acute and chronic neurological conditions as well as a discovery program targeting opportunities in the neurosciences and oncology. For more information visit www.neurenpharma.com.

For more information, contact:

Larry Glass, co-CEO Neuren (USA) T: +1 301 758 2987
Andrew Geddes, Seed Media T: +61 408 677 734